

## Special Issue

# New and Emerging Target-Oriented Drugs for Atopic Dermatitis

### Message from the Guest Editor

Atopic dermatitis (AD) is a clinically heterogeneous inflammatory skin condition that has a great impact on patients' daily activities that remains difficult to treat. The pathophysiology of AD is thought to be a result of the interaction between various critical factors, such as epidermal barrier disruption, genetic susceptibility, activation of distinct subsets of T-cells, environmental triggers, and dysbiosis of commensal skin microbiota. The knowledge acquired over the last decade on AD pathophysiology has led to the development of new targeted therapeutic options, including biologic agents and small molecules, that enable clinicians to better manage AD patients. The main therapeutic targets include cytokines related to Th2 inflammation and their intracellular JAK-STAT signalling pathway, but many other agents (topical, oral, and parenteral drugs) with different targets are in the pipeline. This Special Issue aims to review recent and future therapy development for the treatment of atopic dermatitis.

### Guest Editor

Prof. Dr. Tiago Torres

1. Department of Dermatology, Centro Hospitalar Universitário do Porto, Porto, Portugal
2. Instituto de Ciências Biomédicas Abel Salazar, University of Porto, Porto, Portugal

### Deadline for manuscript submissions

closed (28 February 2023)



## Pharmaceutics

an Open Access Journal  
by MDPI

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/si/117162](https://mdpi.com/si/117162)

*Pharmaceutics*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[pharmaceutics@mdpi.com](mailto:pharmaceutics@mdpi.com)

[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





# Pharmaceutics

---

an Open Access Journal  
by MDPI

---

Impact Factor 5.5  
CiteScore 10.0  
Indexed in PubMed



[mdpi.com/journal/  
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



## About the Journal

### Message from the Editor-in-Chief

*Pharmaceutics* (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

---

### Editor-in-Chief

Prof. Dr. Patrick J. Sinko  
Department of Pharmaceutics, Ernest Mario School of Pharmacy,  
Rutgers University, Piscataway, NJ 08854, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).